Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,690 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Men Clear all
Completed Phase 2 Interventional Results available

A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

NCT01981122
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
sipuleucel-T, enzalutamide
Biological · Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men

NCT03455075
View directory record Official record
Conditions
Healthy, Men, Male Contraception
Interventions
Dimethandrolone-Undecanoate, Levonorgestrel 0.03 MG, Placebo oral capsule
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 31, 2026, 5:18 AM EDT
Terminated Phase 3 Interventional

Open-Label Study of ARD-0403 in Testosterone Deficient Men

NCT00562731
View directory record Official record
Conditions
Hypogonadism
Interventions
ARD-0403
Drug
Lead sponsor
Ardana Bioscience Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Stanford, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Not applicable Interventional

Tailoring a Lifestyle Intervention to Address Obesity Disparities Among Men

NCT03037502
View directory record Official record
Conditions
Weight Loss, Obesity
Interventions
Tailor Made: Solutions for your health (A su Medida: Soluciones para su salud)
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
35 Years to 64 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Miami, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Phase 4 Interventional

Mild To Moderate Erectile Dysfunction Study

NCT00137072
View directory record Official record
Conditions
Impotence
Interventions
Viagra (Sildenafil Citrate) 100 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
33
States / cities
Birmingham, Alabama • Homewood, Alabama • Hoover, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 31, 2026, 5:18 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

NCT05878951
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Phase 4 Interventional

Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement

NCT00752869
View directory record Official record
Conditions
Hypogonadism
Interventions
dutasteride, placebo
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Examining Community-based Effectiveness of a Substance Use and HIV Risk Reduction Intervention for Young Men of Color

NCT03488914
View directory record Official record
Conditions
Substance Use, Sexual Risk
Interventions
YMHP Intervention, Enhanced Treatment as Usual
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
15 Years to 29 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
2
States / cities
Brooklyn, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

NCT02514213
View directory record Official record
Conditions
Prostate Cancer
Interventions
2mg INO-5150 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 and electroporation device CELLECTRA®-5P, 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P, Electroporation using CELLECTRA®-5P
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Baltimore, Maryland • Detroit, Michigan • Omaha, Nebraska + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Not applicable Interventional

Short-term Impact of Cyplexinol® on Self-reported Joint Pain

NCT04764110
View directory record Official record
Conditions
Joint Pain
Interventions
Cyplexinol, Placebo
Dietary Supplement · Other
Lead sponsor
University of Memphis
Other
Eligibility
30 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sequential Vaccinations in Prostate Cancer Patients

NCT00060528
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Recombinant Fowlpox-GM-CSF, Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM), Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM), Recombinant Human GM-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 31, 2026, 5:18 AM EDT
Recruiting Phase 3 Interventional

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

NCT06274047
View directory record Official record
Conditions
Androgen Axis Suppression, Prostatectomy, Prostate Cancer
Interventions
Apalutamide, Androgen Deprivation Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Gilbert, Arizona • Chicago, Illinois • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis

NCT02025751
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 31, 2026, 5:18 AM EDT
Withdrawn Not applicable Interventional

Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients

NCT05156372
View directory record Official record
Conditions
Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma
Interventions
High Intensity Interval Training
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

NCT00427219
View directory record Official record
Conditions
Benign Prostatic Hypertrophy
Interventions
Ozarelix, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
50 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 31, 2026, 5:18 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

NCT07218211
View directory record Official record
Conditions
HIV Prevention, HIV Pre-exposure Prophylaxis, HIV Prevention Program, HIV Prevention and Care, HIV Pre-exposure Prophylaxis Use
Interventions
Lenacapavir long-acting
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

NCT03103646
View directory record Official record
Conditions
Cytochrome P450 Interaction
Interventions
Lu AF35700, Itraconazole (200 mg), Itraconazole (300 mg)
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

eTest: Real-time, Remote Monitoring System for Home-based HIV Testing Among High-risk Men Who Have Sex With Men

NCT03654690
View directory record Official record
Conditions
HIV Infections
Interventions
HIV self-test, Counseling
Diagnostic Test · Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
811 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Not applicable Interventional

PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy

NCT03635866
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fluciclovine PET/MRI
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 31, 2026, 5:18 AM EDT
Recruiting Phase 2 Interventional

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

NCT06347705
View directory record Official record
Conditions
Prostate Cancer
Interventions
2141-V11 Antibody
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Osteoarthritis Pain, Morphine, and Placebo on Neuroendocrine Function in Men

NCT00088296
View directory record Official record
Conditions
Osteoarthritis
Interventions
Blood Draw
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
30 Years to 65 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Not applicable Interventional

UroLift System With SAbR for Prostate Cancer and BPH

NCT05311527
View directory record Official record
Conditions
Prostate Cancer
Interventions
Urolift, SABR
Device · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 31, 2026, 5:18 AM EDT
Recruiting Phase 2Phase 3 Interventional

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

NCT07444723
View directory record Official record
Conditions
Primary Hyperparathyroidism, Parathyroid Cancer, Multiple Endocrine Neoplasias, Heritable Hyperparathyroidism, Hyperparathyroid-jaw Tumor Syndrome
Interventions
18F-FCH, NeuroEXPLORER
Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile-health (mHealth) Intervention to Support HIV Self-testing and PrEP Uptake Among Young Men Who Have Sex With Men

NCT04865341
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
IMB, Information-Only Control
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
17 Years to 24 Years · Male only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 5:18 AM EDT